Ligand to Offer $550M Convertible Notes, Funds XOMA Deal & Share Buyback
LGND has more than doubled off its 52-week low of $110 on elevated volume (2.7× avg).
Summary
Ligand Pharmaceuticals announced a proposed $550 million offering of convertible senior notes due 2031. This significant capital raise, representing about 10% of the company's market cap, provides substantial financial flexibility. A portion of the proceeds will fund convertible note hedge transactions to reduce potential dilution, and up to $75 million will be used for share repurchases. The remaining funds are earmarked for general corporate purposes, including investments and the recently announced $739 million acquisition of XOMA Royalty Corporation. While convertible notes carry potential future dilution, the company's mitigation strategies and strategic use of funds are key.
At the time of this announcement, LGND was trading at $266.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $110.00 to $276.20. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.